News
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
The drugmaker Novo Nordisk is slated to report its second-quarter financial results early Wednesday, after shares plunged ...
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...
Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...
Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.
Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...
The Manila Times on MSN14m
Novo Nordisk posts strong Q2 results
Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit on Wednesday, but rising competition is weighing on sales of its diabetes and obesity treatments Ozempic and ...
Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop ...
Super Micro, AMD, and Snap stocks tumbled after quarterly earnings reports. Arista and Disney stocks were rising.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback